US5580856A
(en)
|
1994-07-15 |
1996-12-03 |
Prestrelski; Steven J. |
Formulation of a reconstituted protein, and method and kit for the production thereof
|
WO1996032096A1
(en)
|
1995-04-14 |
1996-10-17 |
Inhale Therapeutic Systems |
Powdered pharmaceutical formulations having improved dispersibility
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
JPH11510170A
(en)
|
1995-07-27 |
1999-09-07 |
ジェネンテック インコーポレーテッド |
Protein Formula
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
EP0973804B1
(en)
|
1997-04-07 |
2006-12-27 |
Genentech, Inc. |
Anti-vegf antibodies
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
AUPP494798A0
(en)
|
1998-07-29 |
1998-08-20 |
Pacific Biolink Pty Limited |
Protective protein formulation
|
IL146890A0
(en)
|
1999-06-08 |
2002-08-14 |
Regeneron Pharma |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
US7396664B2
(en)
|
1999-06-08 |
2008-07-08 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
US6833349B2
(en)
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
US7303746B2
(en)
|
1999-06-08 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating eye disorders with modified chimeric polypeptides
|
US7306799B2
(en)
|
1999-06-08 |
2007-12-11 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF inhibitors for treatment of eye disorders
|
US6586574B1
(en)
|
1999-08-17 |
2003-07-01 |
Nn A/S |
Stabilization of freeze-dried cake
|
AU1344102A
(en)
|
2000-10-12 |
2002-04-22 |
Genentech Inc |
Reduced-viscosity concentrated protein formulations
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
MXPA04000747A
(en)
|
2001-07-25 |
2004-07-08 |
Protein Desing Labs Inc |
Stable lyophilized pharmaceutical formulation of igg antibodies.
|
WO2003035051A2
(en)
|
2001-10-19 |
2003-05-01 |
Inhale Therapeutic Systems, Inc. |
The use of proton sequestering agents in drug formulations
|
US20050123509A1
(en)
|
2001-10-19 |
2005-06-09 |
Lehrman S. R. |
Modulating charge density to produce improvements in the characteristics of spray-dried proteins
|
PT1441589E
(en)
|
2001-11-08 |
2012-08-13 |
Abbott Biotherapeutics Corp |
Stable liquid pharmaceutical formulation of igg antibodies
|
JP4583762B2
(en)
|
2002-02-27 |
2010-11-17 |
イミュネックス・コーポレーション |
Polypeptide preparation
|
BRPI0403964B8
(en)
|
2003-04-04 |
2021-05-25 |
Genentech Inc |
stable liquid formulations, article of manufacture and use of these formulations for the treatment of ige-mediated dysfunction
|
US7399612B2
(en)
|
2003-06-30 |
2008-07-15 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
AR046510A1
(en)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
COMPOSITION OF A VEGF ANTAGONIST AND AN ANTI-PROLIFERATIVE AGENT
|
CA2534197A1
(en)
|
2003-08-06 |
2005-02-24 |
Thomas Jefferson University |
Use of a vegf antagonist in combination with radiation therapy
|
US20050196340A1
(en)
|
2003-08-06 |
2005-09-08 |
Jocelyn Holash |
Use of a VEGF antagonist in combination with radiation therapy
|
ES2388138T3
(en)
|
2003-08-27 |
2012-10-09 |
Ophthotech Corporation |
Combination therapy for the treatment of ocular neovascular disorders
|
WO2005121176A1
(en)
|
2004-06-08 |
2005-12-22 |
Chengdu Kanghong Biotechnologies Co. Ltd |
Angiogenesis-inhibiting chimeric protein and the use
|
JO3000B1
(en)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
Antibody Formulations.
|
SI1802334T1
(en)
|
2004-10-21 |
2012-12-31 |
Genentech, Inc. |
Method for treating intraocular neovascular diseases
|
LT2586459T
(en)
*
|
2005-03-25 |
2017-09-25 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations
|
ES2776657T3
(en)
|
2005-06-14 |
2020-07-31 |
Amgen Inc |
Self-buffering protein formulations
|
WO2007014073A2
(en)
|
2005-07-22 |
2007-02-01 |
Amgen Inc. |
Concentrated protein lyophilates, methods, and uses
|
JP2009504571A
(en)
|
2005-07-25 |
2009-02-05 |
トルービオン ファーマスーティカルズ インコーポレイテッド |
Compositions and methods for protein dissociation
|
BRPI0618893A2
(en)
|
2005-11-22 |
2011-09-13 |
Wyeth Corp |
immunoglobulin fusion protein formulations
|
JP5405122B2
(en)
|
2005-12-21 |
2014-02-05 |
ワイス・エルエルシー |
Low viscosity protein formulations and uses thereof
|
FR2895258B1
(en)
|
2005-12-22 |
2008-03-21 |
Aventis Pharma Sa |
COMBINATION COMPRISING COMBRETASTATIN AND ANTICANCER AGENTS
|
AU2007212147A1
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
TW200806317A
(en)
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
US8216575B2
(en)
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
CN100502945C
(en)
|
2006-03-31 |
2009-06-24 |
成都康弘生物科技有限公司 |
Application of fusion protein of VEGF receptor for treating disease of eye
|
LT2944306T
(en)
|
2006-06-16 |
2021-02-25 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations suitable for intravitreal administration
|
WO2009015345A1
(en)
|
2007-07-25 |
2009-01-29 |
Amgen Inc. |
Pharmaceutical compositions comprising fc fusion proteins
|
PE20091174A1
(en)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
|
WO2010017296A1
(en)
|
2008-08-05 |
2010-02-11 |
Wyeth |
Lyophilization above collapse
|
US8623395B2
(en)
|
2010-01-29 |
2014-01-07 |
Forsight Vision4, Inc. |
Implantable therapeutic device
|
WO2010148321A1
(en)
|
2009-06-18 |
2010-12-23 |
Wyeth Llc |
Slow dissolution method for reconstitution of lyophilized material
|
WO2010148337A1
(en)
|
2009-06-18 |
2010-12-23 |
Wyeth Llc |
Lyophilized formulations for small modular immunopharmaceuticals
|
CA2765220A1
(en)
|
2009-07-14 |
2011-01-20 |
Biogen Idec Ma Inc. |
Methods for inhibiting yellow color and peroxide formation in a composition
|
US20120121580A1
(en)
|
2009-07-28 |
2012-05-17 |
Merck Sharp & Dohme Corp. |
Methods for producing high concentration lyophilized pharmaceutical formulations
|
JP2013501058A
(en)
|
2009-08-04 |
2013-01-10 |
ジェネンテック, インコーポレイテッド |
Concentrated polypeptide formulation with reduced viscosity
|
US20130029909A1
(en)
|
2009-09-15 |
2013-01-31 |
John Ryan |
Treatment of cancer
|
MX2012009755A
(en)
|
2010-02-26 |
2012-09-12 |
Novo Nordisk As |
Stable antibody containing compositions.
|
WO2011109365A2
(en)
|
2010-03-01 |
2011-09-09 |
Progenics Pharmaceuticals, Inc. |
Concentrated protein formulations and uses thereof
|
EP2566510A1
(en)
|
2010-05-03 |
2013-03-13 |
F. Hoffmann-La Roche AG |
Compositions and methods useful for reducing the viscosity of protein-containing formulations
|
EP2588138A1
(en)
|
2010-07-02 |
2013-05-08 |
Genentech, Inc. |
Treatment of vascularized pigment epithelial detachment with anti-vegf therapy
|
EP2600920A4
(en)
|
2010-08-05 |
2017-10-04 |
Forsight Vision4, Inc. |
Subconjunctival implant for posterior segment drug delivery
|
CN103816115B
(en)
*
|
2010-08-31 |
2017-06-27 |
成都康弘生物科技有限公司 |
A kind of pharmaceutical composition containing the fusion protein for suppressing blood vessel hyperplasia and purposes
|
KR20200077622A
(en)
|
2011-01-13 |
2020-06-30 |
리제너론 파아마슈티컬스, 인크. |
Use of a vegf antagonist to treat angiogenic eye disorders
|
PL2701773T3
(en)
|
2011-04-25 |
2019-09-30 |
Icon Bioscience, Inc. |
Dose guides for injection syringe
|
JO3283B1
(en)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
|
JP6176849B2
(en)
|
2011-07-19 |
2017-08-09 |
中外製薬株式会社 |
A stable protein-containing preparation containing arginine amide or a similar compound
|
CN108771655A
(en)
|
2011-10-28 |
2018-11-09 |
诚信生物公司 |
Protein formulation containing amino acid
|
GB201122408D0
(en)
|
2011-12-23 |
2012-02-08 |
Univ Strathclyde |
Method for preparing dry protein formulations
|
SG11201403792TA
(en)
|
2012-01-23 |
2014-10-30 |
Regeneron Pharma |
Stabilized formulations containing anti-ang2 antibodies
|
DK3858405T3
(en)
|
2012-06-01 |
2023-07-03 |
Novartis Ag |
SYRINGE
|
TW201400122A
(en)
|
2012-06-01 |
2014-01-01 |
Ophthotech Corp |
Compositions comprising an anti-PDGF aptamer and a VEGF antagonist
|
US20130323242A1
(en)
|
2012-06-01 |
2013-12-05 |
Ophthotech Corp. |
Compositions comprising an anti-pdgf aptamer and a vegf antagonist
|
JP2015519382A
(en)
|
2012-06-12 |
2015-07-09 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Pharmaceutical formulations for therapeutic antibodies
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
US9474803B2
(en)
|
2012-11-27 |
2016-10-25 |
Alteogen Inc. |
Composition for stabilizing fusion protein in which protein and FC domain are fused
|
EP3003369A4
(en)
|
2013-05-28 |
2017-04-26 |
Momenta Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising pyrophosphate
|
BR112016000937A8
(en)
|
2013-07-18 |
2021-06-22 |
Mannkind Corp |
dry powder pharmaceutical formulations, method for making a dry powder formulation and use of a dry powder pharmaceutical formulation
|
ES2773317T3
(en)
|
2013-11-05 |
2020-07-10 |
Allergan Inc |
Method of treating eye conditions with an anti-VEGF DARPin
|
EP3492495A1
(en)
|
2014-05-12 |
2019-06-05 |
Formycon AG |
Pre-filled plastic syringe containing a vegf antagonist
|
US10478498B2
(en)
|
2014-06-20 |
2019-11-19 |
Reform Biologics, Llc |
Excipient compounds for biopolymer formulations
|
AU2015280480A1
(en)
|
2014-06-26 |
2017-01-05 |
Amgen Inc. |
Protein formulations
|
KR102486321B1
(en)
|
2014-07-18 |
2023-01-09 |
사노피 |
Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
|
CN104940926B
(en)
|
2014-09-25 |
2017-09-22 |
信达生物制药(苏州)有限公司 |
Recombination fusion protein preparation
|
CN105435222B
(en)
|
2014-09-25 |
2018-05-29 |
信达生物制药(苏州)有限公司 |
Recombination fusion protein preparation
|
TWI705827B
(en)
|
2014-11-07 |
2020-10-01 |
瑞士商諾華公司 |
Methods for treating ocular diseases
|
US20160144025A1
(en)
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
CN112826934A
(en)
|
2014-12-11 |
2021-05-25 |
拜耳医药保健有限责任公司 |
Treatment of age-related macular degeneration with small active choroidal neovascularisation
|
KR101846306B1
(en)
*
|
2015-03-31 |
2018-05-18 |
일동제약(주) |
Pharmaceutical compositions for preventing and treating of eye diseases comprising fusion protein of tissue permeable peptide and anti-VEGF agent
|
MX2017016324A
(en)
|
2015-06-16 |
2018-03-02 |
Merck Patent Gmbh |
Pd-l1 antagonist combination treatments.
|
KR101808234B1
(en)
*
|
2015-06-23 |
2017-12-12 |
(주)알테오젠 |
A stable liquid formulation of fusion protein with IgG Fc domain
|
EP3352790A1
(en)
|
2015-09-22 |
2018-08-01 |
Pfizer Inc |
Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
|
WO2017053807A2
(en)
|
2015-09-23 |
2017-03-30 |
Genentech, Inc. |
Optimized variants of anti-vegf antibodies
|
CA3001346A1
(en)
|
2015-10-16 |
2017-04-20 |
Regeneron Pharmaceuticals, Inc. |
Stable protein compositions
|
US20180326126A1
(en)
|
2015-11-18 |
2018-11-15 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
EP3377100A1
(en)
|
2015-11-18 |
2018-09-26 |
Formycon AG |
Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
|
WO2017095848A1
(en)
|
2015-11-30 |
2017-06-08 |
Medimmune, Llc |
Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
|
JP2019501200A
(en)
|
2016-01-08 |
2019-01-17 |
クリアサイド バイオメディカル,インコーポレイテッド |
Methods and devices for treating posterior ocular disorders with aflibercept and other biologics
|
EP3407868A1
(en)
|
2016-01-26 |
2018-12-05 |
Formycon AG |
Liquid formulation of a vegf antagonist
|
EP3443346B1
(en)
|
2016-04-13 |
2023-08-30 |
Medimmune, LLC |
Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
|
US10279048B2
(en)
|
2016-07-13 |
2019-05-07 |
Reform Biologics, Llc |
Stabilizing excipients for therapeutic protein formulations
|
JP7114567B2
(en)
|
2016-08-17 |
2022-08-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Process for the preparation of highly concentrated liquid formulations containing biomolecules
|
PL3500856T3
(en)
|
2016-08-18 |
2021-04-19 |
Regeneron Pharmaceuticals, Inc. |
Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy
|
WO2018063963A1
(en)
|
2016-09-28 |
2018-04-05 |
Board Of Regents, The University Of Texas System |
Antibody and protein therapeutic formulations and uses thereof
|
EA201990900A1
(en)
*
|
2016-10-07 |
2019-07-31 |
Ридженерон Фармасьютикалз, Инк. |
LIOPHILIZED PROTEIN STABLE AT ROOM TEMPERATURE
|
WO2018094316A1
(en)
|
2016-11-21 |
2018-05-24 |
Just Biotherapeutics, Inc. |
Aflibercept formulations and uses thereof
|
US11000518B2
(en)
|
2016-12-01 |
2021-05-11 |
Jiangsu Hengrui Medicine Co., Ltd. |
Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer
|
US11123411B2
(en)
|
2016-12-08 |
2021-09-21 |
Gary E. Borodic |
Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
|
PE20191436A1
(en)
|
2016-12-23 |
2019-10-14 |
Serum Institute Of India Pvt Ltd |
IMPROVED METHODS TO STIMULATE ANTIBODY PRODUCTIVITY IN MAMMAL CELL CULTURE AND REDUCE AGGREGATION DURING POST-TREATMENT FORMULATION PROCESSES (DOWNSTREAM) AND STABLE ANTIBODY FORMULATIONS OBTAINED FROM MAMMAL CELLS
|
US10617756B2
(en)
|
2017-01-05 |
2020-04-14 |
Shimojani, LLC |
Drug regimen for treatment of cerebral ischemia
|
KR101861163B1
(en)
|
2017-04-26 |
2018-05-25 |
삼천당제약주식회사 |
Ophthalmic pharmaceutical composition
|
US10646569B2
(en)
|
2017-05-16 |
2020-05-12 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
WO2018217995A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
US20200108064A1
(en)
|
2017-06-08 |
2020-04-09 |
Eye Therapies, Llc |
Low-dose brimonidine combinations and uses thereof
|
TW201904610A
(en)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
Non-antibody vegf antagonists for the treatment of neovascular glaucoma
|
US11077059B2
(en)
|
2017-07-25 |
2021-08-03 |
Elektrofi, Inc. |
Electrospraying formation of particles including agents
|
WO2019020777A1
(en)
*
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
Liquid formulation of a vegf antagonist
|
WO2019036619A1
(en)
|
2017-08-18 |
2019-02-21 |
Reform Biologics, Llc |
Stabilizing excipients for therapeutic protein formulations
|
IT201700101582A1
(en)
|
2017-09-12 |
2019-03-12 |
Milano Politecnico |
Device for intraocular release
|
WO2019055902A1
(en)
*
|
2017-09-18 |
2019-03-21 |
Amgen Inc. |
Vegfr-fc fusion protein formulations
|
US20200283492A1
(en)
|
2017-09-29 |
2020-09-10 |
Hanmi Pharm Co., Ltd. |
Long acting protein complex having an enhanced efficiency
|
US11246846B2
(en)
|
2017-10-23 |
2022-02-15 |
Michael S. Tempesta |
Trisodium citrate compositions having enhanced uptake across digestive mucosa
|
AU2018370135A1
(en)
|
2017-11-16 |
2020-06-04 |
Iveric Bio, Inc. |
A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (IPCV)
|
AU2018368466A1
(en)
|
2017-11-17 |
2020-06-18 |
Amgen Inc. |
VEGFR-Fc fusion protein formulations
|
WO2019099965A1
(en)
|
2017-11-20 |
2019-05-23 |
Just Biotherapeutics, Inc. |
Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
|
MX2020005166A
(en)
|
2017-11-30 |
2020-09-03 |
Regeneron Pharma |
Use of a vegf antagonist to treat angiogenic eye disorders.
|
AU2018380174A1
(en)
|
2017-12-06 |
2020-05-21 |
Jiangsu Hengrui Medicine Co., Ltd. |
Use of PARP inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
|
KR102494021B1
(en)
|
2017-12-22 |
2023-02-06 |
삼성바이오에피스 주식회사 |
Liquid composition containing VEGF antagonist
|
SG11202007130RA
(en)
|
2018-01-26 |
2020-08-28 |
Univ California |
Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
|
US11426446B2
(en)
|
2018-03-08 |
2022-08-30 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
WO2019173767A1
(en)
|
2018-03-08 |
2019-09-12 |
Coherus Biosciences Inc. |
Stable aqueous formulations of aflibercept
|
SG11202010100QA
(en)
|
2018-04-12 |
2020-11-27 |
Amgen Inc |
Methods for making stable protein compositions
|
CN108671229B
(en)
|
2018-05-08 |
2022-03-25 |
华博生物医药技术(上海)有限公司 |
Pharmaceutical composition preparation of recombinant human vascular endothelial growth factor receptor-antibody fusion protein
|
JP7235770B2
(en)
|
2018-05-10 |
2023-03-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Formulations Containing High Concentrations of VEGF Receptor Fusion Proteins
|
TW202011995A
(en)
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
High concentration liquid antibody formulations
|
EP3851096A4
(en)
|
2018-09-10 |
2022-07-06 |
Samsung Bioepis Co., Ltd. |
Liquid composition comprising protein
|
US20210353713A1
(en)
|
2018-10-26 |
2021-11-18 |
Amgen Inc. |
Formulations comprising a tris buffer and a protein
|
CN110664757B
(en)
|
2018-11-19 |
2022-08-02 |
成都瑞沐生物医药科技有限公司 |
Nanocrystalline eye drop, preparation method and application thereof
|
KR20210093976A
(en)
|
2018-11-21 |
2021-07-28 |
리제너론 파아마슈티컬스, 인크. |
High-concentration protein formulation
|
MA54511B1
(en)
|
2018-12-20 |
2023-04-28 |
Thea Lab |
Nutraceutical ophthalmic composition for the treatment of retinal pathologies with a neovascular component
|
US20220098279A1
(en)
|
2019-01-30 |
2022-03-31 |
Amgen Inc. |
Aflibercept attributes and methods of characterizing and modifying thereof
|
KR20210128434A
(en)
|
2019-02-11 |
2021-10-26 |
서로젠, 인크. |
Regulation of WNT signaling in ocular disorders
|
US20220143137A1
(en)
|
2019-02-13 |
2022-05-12 |
Novaliq Gmbh |
Compositions and methods for the treatment of ocular neovascularization
|
US20200390725A1
(en)
|
2019-06-17 |
2020-12-17 |
Sol-Gel Technologies Ltd. |
Treatment of ocular diseases with ophthalmic tapinarof compositions
|
US20200390724A1
(en)
|
2019-06-17 |
2020-12-17 |
Sol-Gel Technologies Ltd. |
Treatment of ocular diseases with ophthalmic tapinarof compositions
|
WO2020255135A1
(en)
|
2019-06-17 |
2020-12-24 |
Sol-Gel Technologies Ltd. |
Treatment of ocular inflammatory diseases with topical ophthalmic tapinarof compositions
|
CA3131052A1
(en)
|
2019-03-25 |
2020-10-01 |
Soon Jae Park |
Pharmaceutical composition for subcutaneous injection comprising human hyaluronidase ph20 variant and drug
|
KR20210145152A
(en)
|
2019-04-01 |
2021-12-01 |
제넨테크, 인크. |
Compositions and methods for stabilization of protein-containing formulations
|
CA3134538A1
(en)
|
2019-04-03 |
2020-10-08 |
Denali Therapeutics Inc. |
Formulations of protein molecules comprising iduronate 2-sulfatase
|
WO2020219550A1
(en)
|
2019-04-23 |
2020-10-29 |
Amgen Inc. |
The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations
|
EP3736574A1
(en)
|
2019-05-07 |
2020-11-11 |
Atlas Antibodies AB |
A formulation comprising an isotope labeled fusion polypeptide
|
WO2020239051A1
(en)
|
2019-05-30 |
2020-12-03 |
江苏恒瑞医药股份有限公司 |
Uses of cdk4/6 inhibitor jointly with vegfr inhibitor in preparing tumor-treating medicament
|
CN114206381A
(en)
|
2019-07-10 |
2022-03-18 |
瑞泽恩制药公司 |
Compositions with reduced host cell protein levels and methods of making the same
|
US20210100856A1
(en)
|
2019-09-11 |
2021-04-08 |
Adverum Biotechnologies, Inc. |
Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
|
WO2021048779A2
(en)
|
2019-09-12 |
2021-03-18 |
Lupin Limited |
Modified dosing of vegf inhibitors for ophthalmic use
|
US20220340630A1
(en)
|
2019-09-13 |
2022-10-27 |
National Science And Technology Development Agency |
Composition of renaturation buffer solution for dimeric proteins and method of renaturation dimeric proteins using the composition thereof
|
JP2022548150A
(en)
|
2019-09-17 |
2022-11-16 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Camphorsulfonic acid and its combination with cationic excipients as viscosity reducing agents in highly concentrated protein formulations
|